Skip to main content
My Experience
Login Required
Program
Full Program
Browse By Date
Friday, April 22, 2022
Saturday, April 23, 2022
Sunday, April 24, 2022
Browse By Title
Browse By Presenter
CME Program
Non-CME Industry Sessions
Abstracts and ePosters
Browse by Track
Browse by Presenter
Sponsors
Login Required
Attendees
Login Required
CME and Evaluation Information
Login Required
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Toggle navigation
Login
Search
Home
My Experience
Login Required
Program
Full Program
Browse By Date
Friday, April 22, 2022
Saturday, April 23, 2022
Sunday, April 24, 2022
Browse By Title
Browse By Presenter
CME Program
Non-CME Industry Sessions
Abstracts and ePosters
Browse by Track
Browse by Presenter
Sponsors
Login Required
Attendees
Login Required
CME and Evaluation Information
Login Required
Meeting Info and FAQ
My User Profile
Login Required
Kidney Cancer Association Info
Upcoming IKCS Meetings
Tweets by 2022 IKCS: Europe
Icon Legend
This session is not in your schedule.
This session is in your schedule. Click again to remove it.
Home
Browse by Poster Presenter
Browse by Poster Presenter
30 results found
Type here to filter the list
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
A
Alonso-Gordoa, Teresa
Hospital Universitario Ramón y Cajal
13
:
Complete Responses with first line (1L) antiangiogenic monotherapy in Spanish patients with metastatic renal cell carcinoma (mRCC). The ATILA study
Teresa Alonso-Gordoa
Favorite
B
Barth, Dominik
Division of Oncology, Department of Internal Medicine, Medical University of Graz
19
:
From cytokine to immunotherapy: Improvements in overall survival in metastatic renal cell carcinoma in a real-life population in Austria upon 3 decades of follow-up
Dominik Barth
Favorite
Bergerot, Cristiane
Centro de Cancer de Brasilia, Instituto Unity de Ensino e Pesquisa
2
:
Relevance of items in the FACT Kidney Cancer Symptom Inventory-19 (FKSI-19): Results of a patient survey
Cristiane Bergerot
Favorite
Beyer, Katharina
Translational Oncology and Urology Research (TOUR), King’s College London, London, UK
3
:
A systematic review of heterogeneity in outcome reporting, definition and measurement in localised kidney cancer
Katharina Beyer
Favorite
Björkqvist, Josefine
Academic Urology Unit, University of Aberdeen, Aberdeen, UK and International Kidney Cancer Coalition, Duivendrecht, the Netherlands
11
:
Retention in clinical trials: the kidney cancer patient perspective
Josefine Björkqvist
Favorite
Buckland, Benjamin
Urology Department, John Hunter Hospital
27
:
Renal cell carcinoma in a patient with Situs Inversus Totalis – Laparoscopic radical nephrectomy is a safe and feasible option: A case report
Benjamin Buckland
Favorite
C
Carril-Ajuria, Lucia
Institute Gustave Roussy, Villejuif, France. University Hospital 12 de Octubre, Madrid, Spain.
12
:
Efficacy of frontline combination therapy in metastatic renal cell carcinoma (mRCC) patients (pts) with poor performance status (PS)
Lucia Carril-Ajuria
Favorite
23
:
Relationship between circulating immune markers and tertiary lymphoid structures (TLS) in metastatic renal cell carcinoma (mRCC) patients (pts) treated with nivolumab within the NIVOREN study.
Lucia Carril-Ajuria
Favorite
24
:
Circulating microRNAs and treatment response to cabozantinib in metastatic clear cell renal cell carcinoma (mRCC) patients treated in the phase II CABOPRE trial.
Lucia Carril-Ajuria
Favorite
D
Dabestani, Saeed
Lund University, Dept. of Translational Medicine, Division of Urological Cancers, Kristianstad Central Hospital, Malmo, Sweden
31
:
AURORAX-0087A: Glycosaminoglycan (GAG) scores for recurrence detection in Leibovich Points ≥5 clear cell renal cell carcinoma - Trial In Progress
Saeed Dabestani
Favorite
de Cubas, Aguirre
Medical University of South Carolina
5
:
SETD2 loss in kidney cancer - Setting the stage for synthetic lethality
Aguirre de Cubas
Favorite
E
Escudier, Bernard
Institut Gustave-Roussy
1
:
Nivolumab plus ipilimumab plus cabozantinib for previously untreated advanced renal cell carcinoma: results from a discontinued study arm of CheckMate 9ER
Bernard Escudier
Favorite
G
Gauthier, Kelsey
Arcus Biosciences
21
:
AB521 is a Novel and Potent Clinical-stage HIF-2α Inhibitor for the Treatment of Renal Cell Carcinoma
Kelsey Gauthier
Favorite
Geertsen, Louise
Department of Urology, Odense University Hospital, Denmark
26
:
Circulating tumor DNA in patients with renal cell carcinoma. A systematic review of the literature
Louise Geertsen
Favorite
Goebell, Peter
Urologische und Kinderurologische Universitätsklinik, Erlangen
16
:
Sequential treatment patterns over time for advanced renal cell carcinoma: data from the German research platform CARAT
Peter Goebell
Favorite
Grünwald, Viktor
University-Hospital Essen
14
:
Real-World Clinical Outcomes of tivozanib as first-line treatment of metastatic renal cell carcinoma in Germany
Viktor Grünwald
Favorite
H
Hutson, Thomas
Texas Oncology
18
:
Post Hoc Analysis of the CLEAR Study in Advanced Renal Cell Carcinoma (aRCC): Subsequent Therapy and Survival Outcomes with Lenvatinib (L) + Everolimus (E) vs Sunitinib (S)
Thomas Hutson
Favorite
I
Ince, Will
Addenbooke's Hospital
4
:
‘Real world’ impact of immune checkpoint inhibitors (ICI) on survival in metastatic renal cell cancer (mRCC)
Will Ince
Favorite
L
Lewiz Habib, Samy
UT Health San Antonio, TX, USA
7
:
New Evidence of Preventing Kidney Tumor Progression in Pre-clinical Mouse Model
Samy Lewiz Habib
Favorite
M
Malhotra, Jasnoor
City of Hope Comprehensive Cancer Center
10
:
Waning efficacy of COVID-19 vaccination at 6 months in patients with renal cell carcinoma (RCC)
Jasnoor Malhotra
Favorite
Meza Contreras, Luis
City of Hope Comprehensive Cancer Center
25
:
Ultra-sensitive circulating tumor DNA (ctDNA) assay distinguishes partial response (PR) and complete response (CR) with immunotherapy in metastatic renal cell carcinoma (mRCC)
Luis Meza Contreras
Favorite
Motzer, Robert
Memorial Sloan Kettering Cancer Center
22
:
Characterization and Management of Adverse Reactions in Patients With Advanced Renal Cell Carcinoma Receiving Lenvatinib + Pembrolizumab (CLEAR Study)
Robert Motzer
Favorite
29
:
LITESPARK-011: Belzutifan Plus Lenvatinib Versus Cabozantinib: A Randomized, Open-Label Phase 3 Study in Patients With Advanced Renal Cell Carcinoma (RCC) After Anti–PD-1/PD-L1 Therapy
Robert Motzer
Favorite
O
Osawa, Takahiro
Department of Renal And Genitourinary Surgery Hokkaido University Graduate School of Medicine, Sapporo, Japan
28
:
A Three-Arm Randomized Multicenter Phase II Trial Comparing Patient-Reported Outcome (PRO) Monitoring in Cabozantinib Treatment in Patients with Advanced Renal Cell Carcinoma: ePRO vs paper-PRO, or usual care (Trial in Progress)
Takahiro Osawa
Favorite
R
Rasmussen, Ida Marie
Department of Oncology, Copenhagen University Hospital - Herlev and Gentofte, Denmark
30
:
Trial in Progress: Individualized Treatment Strategy for Patients with Metastatic Non-clear Cell Renal Cell Carcinoma – the INDIGO phase II study
Ida Marie Rasmussen
Favorite
Rodler, Severin
Klinikum der Universität München, Department of Urology
15
:
Image-guided robotic radiosurgery for the treatment of metastases of renal cell carcinoma.
Severin Rodler
Favorite
T
Tenabene, Mohamed Amine
Groupe Jolimont
20
:
Profile of Dissociated response in metastatic Clear Cell Renal Cell Carcinoma and subsequent radical therapy
Mohamed Amine Tenabene
Favorite
U
Unterrainer, Lena
LMU Munich
8
:
PSMA-expression in renal cell carcinoma as basis for theranostic approaches – an immunohistochemical nephrectomy study
Lena Unterrainer
Favorite
Z
Zanotti, Giovanni
Pfizer
17
:
Real-world clinical characteristics and treatment patterns in patients with advanced renal cell carcinoma treated with first-line immunotherapy + axitinib in Germany
Giovanni Zanotti
Favorite
Zengin, Zeynep
City of Hope Comprehensive Cancer Center
9
:
Perceptions of COVID-19 vaccination in patients with renal cell carcinoma (RCC)
Zeynep Zengin
Favorite
Back to Top
